两例血液病患者因多发性洛门托孢子菌引起的真菌血症,结果各不相同

IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES Diagnostic microbiology and infectious disease Pub Date : 2024-09-11 DOI:10.1016/j.diagmicrobio.2024.116527
Fernando Cobo , Pedro Antonio González-Sierra , Mª Carmen Ortega-Gavilán , Leticia Castellano-Sánchez , José María Navarro-Marí
{"title":"两例血液病患者因多发性洛门托孢子菌引起的真菌血症,结果各不相同","authors":"Fernando Cobo ,&nbsp;Pedro Antonio González-Sierra ,&nbsp;Mª Carmen Ortega-Gavilán ,&nbsp;Leticia Castellano-Sánchez ,&nbsp;José María Navarro-Marí","doi":"10.1016/j.diagmicrobio.2024.116527","DOIUrl":null,"url":null,"abstract":"<div><p><em>Lomentospora prolificans</em> is an uncommon cause of invasive fungal disease, but it is associated with high mortality because it is difficult to treat. Most of severe cases are produced in immunossupressed patients, especially in those with neutropenia and/or hematological malignancies. Resistance to the majority of antifungal agents can be still observed. Here we report two cases of <em>L. prolificans</em> fungemia with different outcome, since in one of these patients treatment with one of the new antifungals could be applied. Both patients were treated with different antifungal drugs, but only the second one survived due to therapy with fosmanogepix®. The current treatment is still based on a combination of conventional antifungal drugs, although in much cases this strategy is not sufficient. The introduction of new promising antifungal agents such as fosmanogepix® and olorofim® may open new perspectives in the treatment of invasive infections caused by <em>L. prolificans</em>, as in our patient.</p></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"110 4","pages":"Article 116527"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Two cases of fungemia due to Lomentospora prolificans in haematological patients with different outcome\",\"authors\":\"Fernando Cobo ,&nbsp;Pedro Antonio González-Sierra ,&nbsp;Mª Carmen Ortega-Gavilán ,&nbsp;Leticia Castellano-Sánchez ,&nbsp;José María Navarro-Marí\",\"doi\":\"10.1016/j.diagmicrobio.2024.116527\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><em>Lomentospora prolificans</em> is an uncommon cause of invasive fungal disease, but it is associated with high mortality because it is difficult to treat. Most of severe cases are produced in immunossupressed patients, especially in those with neutropenia and/or hematological malignancies. Resistance to the majority of antifungal agents can be still observed. Here we report two cases of <em>L. prolificans</em> fungemia with different outcome, since in one of these patients treatment with one of the new antifungals could be applied. Both patients were treated with different antifungal drugs, but only the second one survived due to therapy with fosmanogepix®. The current treatment is still based on a combination of conventional antifungal drugs, although in much cases this strategy is not sufficient. The introduction of new promising antifungal agents such as fosmanogepix® and olorofim® may open new perspectives in the treatment of invasive infections caused by <em>L. prolificans</em>, as in our patient.</p></div>\",\"PeriodicalId\":11329,\"journal\":{\"name\":\"Diagnostic microbiology and infectious disease\",\"volume\":\"110 4\",\"pages\":\"Article 116527\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diagnostic microbiology and infectious disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0732889324003535\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic microbiology and infectious disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0732889324003535","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

多形性洛门托孢子菌是一种不常见的侵袭性真菌病,但由于难以治疗,死亡率很高。大多数重症病例都发生在免疫力低下的患者身上,尤其是中性粒细胞减少症和/或血液恶性肿瘤患者。目前仍可观察到对大多数抗真菌药物的耐药性。在此,我们报告了两例增殖体真菌病,结果各不相同,因为其中一名患者可以使用一种新型抗真菌药物进行治疗。这两名患者都接受了不同的抗真菌药物治疗,但只有第二名患者在使用福斯马诺吉匹克®治疗后存活了下来。目前的治疗方法仍以常规抗真菌药物的联合使用为主,但在很多情况下,这种策略并不足够。福斯马诺吉匹克®和奥洛菲姆®等新型抗真菌药物的问世,可能会为治疗像我们的患者一样的增殖体真菌引起的侵袭性感染开辟新的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Two cases of fungemia due to Lomentospora prolificans in haematological patients with different outcome

Lomentospora prolificans is an uncommon cause of invasive fungal disease, but it is associated with high mortality because it is difficult to treat. Most of severe cases are produced in immunossupressed patients, especially in those with neutropenia and/or hematological malignancies. Resistance to the majority of antifungal agents can be still observed. Here we report two cases of L. prolificans fungemia with different outcome, since in one of these patients treatment with one of the new antifungals could be applied. Both patients were treated with different antifungal drugs, but only the second one survived due to therapy with fosmanogepix®. The current treatment is still based on a combination of conventional antifungal drugs, although in much cases this strategy is not sufficient. The introduction of new promising antifungal agents such as fosmanogepix® and olorofim® may open new perspectives in the treatment of invasive infections caused by L. prolificans, as in our patient.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
3.40%
发文量
149
审稿时长
56 days
期刊介绍: Diagnostic Microbiology and Infectious Disease keeps you informed of the latest developments in clinical microbiology and the diagnosis and treatment of infectious diseases. Packed with rigorously peer-reviewed articles and studies in bacteriology, immunology, immunoserology, infectious diseases, mycology, parasitology, and virology, the journal examines new procedures, unusual cases, controversial issues, and important new literature. Diagnostic Microbiology and Infectious Disease distinguished independent editorial board, consisting of experts from many medical specialties, ensures you extensive and authoritative coverage.
期刊最新文献
Cover 2 - Aims/Scopes, Ed Board Successful treatment of infections caused by mycobacterium abscessus complex following aesthetic procedures: A case series in China Diagnostic value of metagenomic next-generation sequencing for bronchoalveolar lavage diagnostics in patients with lower respiratory tract infections Pseudallescheria boydii infection of the bloodstream system: First reported case from China Anti-biofilm activity of carvacrol-thymoquinone nanocarriers on vulvovaginal candidiasis isolates
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1